Physician profile
Ann Sisson
NPI 1780217638
$6,133.67
in general payments reported to CMS, 2019-2025
57 companies · $1,683 in 2025
The $1,683 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $283 · 2022: $1,174 · 2023: $1,171 · 2024: $1,823 · 2025: $1,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,327 · Consulting Fee: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,326.76 |
| Consulting Fee | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $680.51 | 2023-2025 | Calquence, Lynparza, Imfinzi |
| Seagen INC. | $573.86 | 2021-2023 | Padcev, Tukysa, Adcetris |
| Novartis Pharmaceuticals Corporation | $573.62 | 2022-2025 | |
| Beigene USA, INC. | $461.90 | 2022-2025 | Brukinsa, Tevimbra |
| Daiichi Sankyo INC. | $366.18 | 2021-2025 | Enhertu, Datroway |
| Pfizer INC. | $241.14 | 2022-2025 | |
| Celgene Corporation | $197.06 | 2022-2025 | Reblozyl |
| Janssen Biotech, INC. | $196.21 | 2022-2025 | Darzalex, Rybrevant, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $195.26 | 2021-2025 | Opdivo, Opdualag |
| Incyte Corporation | $171.62 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Merck Sharp & Dohme LLC | $145.59 | 2022-2025 | Keytruda |
| Eisai INC. | $135.88 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $126.35 | 2024-2025 | Rybrevant, Erleada, Darzalex |
| Beone Medicines USA, INC. | $125.77 | 2025 | Brukinsa, Tevimbra |
| Pharmacyclics LLC, An Abbvie Company | $113.49 | 2021-2023 | Epkinly, Imbruvica |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Sisson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.